MedTrace Logo

Mechanistic 129 Xe MRI Study to Assess Therapeutic Response in Fibrotic Interstitial Lung Disease

NCT07786090 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 35

Last updated 2026-08-28

No results posted yet for this study

Summary

The goal of this observational study is to better understand how treatment affects the lungs of adults (ages 18-80) with fibrotic interstitial lung diseases. The main questions it aims to answer are:

* Can advanced imaging detect the effect of currently approved therapies on people with fibrotic interstitial lung diseases?
* What is the relationship between the response to therapy and the imaging response to therapy?

Conditions

  • Fibrotic Interstitial Lung Disease

Interventions

OTHER

Hyperpolarized 129Xe MRI

Inhalation of hyperpolarized 129Xe gas followed by breath-hold MRI for ventilation imaging.

Sponsors & Collaborators

  • Dr. Grace Parraga

    lead OTHER

Principal Investigators

  • Grace E Parraga, PHD · Robarts Research Institute, The University of Western Ontario

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-11-30
Primary Completion
2028-11-30
Completion
2029-01-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07786090 on ClinicalTrials.gov